Jon Moore

Company: Epitopea

Job title: Chief Scientific Officer & Co-Founder

Seminars:

Building High-Performance Off-the-shelf Therapeutic Vaccines Based on Shared TSAs from the Cryptic Genome 8:50 am

Epitopea is exploiting a new family of mass spec identified wild-type TSAs derived from so-called non-coding DNA that represent the major opportunity for T cell-mediated control of tumours Configured into a LNP-mRNA vaccine, the mouse counterparts of these antigens control tumour growth as single agents We are configuring human cryptic TSAs into highly effective cancer…Read more

day: Day One